Growth Metrics

Sarepta Therapeutics (SRPT) Other Working Capital Changes (2016 - 2025)

Sarepta Therapeutics has reported Other Working Capital Changes over the past 13 years, most recently at -$20.3 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 71.64% year-over-year to -$20.3 million; the TTM value through Dec 2025 reached $79.8 million, up 348.08%, while the annual FY2025 figure was $69569.0, 100.22% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$20.3 million at Sarepta Therapeutics, down from $159.9 million in the prior quarter.
  • Over five years, Other Working Capital Changes peaked at $159.9 million in Q3 2025 and troughed at -$85.4 million in Q1 2025.
  • A 5-year average of -$5.7 million and a median of -$21.1 million in 2022 define the central range for Other Working Capital Changes.
  • Biggest five-year swings in Other Working Capital Changes: soared 271.0% in 2022 and later tumbled 3788.86% in 2025.
  • Year by year, Other Working Capital Changes stood at -$36.5 million in 2021, then soared by 271.0% to $62.3 million in 2022, then plummeted by 132.21% to -$20.1 million in 2023, then crashed by 256.31% to -$71.5 million in 2024, then skyrocketed by 71.64% to -$20.3 million in 2025.
  • Business Quant data shows Other Working Capital Changes for SRPT at -$20.3 million in Q4 2025, $159.9 million in Q3 2025, and $25.6 million in Q2 2025.